Preparation And Pharmacodynamics Study On Compound Dehydroandrographolide Succinate Injection

Compound Dehydroandrographolide Succinate Injection is the sterile aqueous solution mainly included azithromycin aspartate and Berberine sulfate based on temporary pharmacy technology.Prescription screening,preparation condition,product stability,safety Evaluation, quality detection standards,bacteriostatic test in vitro and clinical Test of Compound Dehydroandrographolide Succinate injection were carried,the results showed that optional conditions of injection with character stability were azithromycin aspartate dissolved in10%ethanol at 45℃,Berberine sulfate dissolved at 90-100℃,pH 6.0-7.5,0.05%EDTA-Na₂ and 0.05%L-cysteine as Stabilizer,the average recovery of azithromycin aspartate was 99.5%based on high performance liquid chromatography, the average recovery of Berberine sulfate was 98.6%based on ultraviolet spectrophotometry analysis.The LD₅₀ of intramuscular injection of mice was 754.8 mg·kg^-1 in acute toxicity test,the confidence range of LD₅₀ was 571.6-996.5 mg·kg^-1.Various diseases were induced,Compound Dehydroandrographolide Succinate as Injection,the results showed that MIC(mg·mL^-1) of Erysipelas and Staphylococcus Aureus was 1+1,MIC (mg·mL^-1) of Escherichia Coli was 0.1+0.1,pasteurellosis bacillus and aureus were 0.01+0.01.When dose of injection was 0.1 mL·kg^-1,twice one day,cure rate of disease was 100%by artificial induction,95%by Natural Infection 3 d later.Based above,Compound Dehydroandrographolide Succinate Injection is a new drug with stable product,clear clinical effect,safety,high quality detection standards and anti-infection Effect,better development Prospect.